Skip to main content

Table 2 Statistical comparisons of five endometrial lesions

From: CyclinD1, a prominent prognostic marker for endometrial diseases

Parameter a vs. Parameter b

Positives (Parameter a)

Positives (Parameter b)

χ2value*

p value*

Simple hyperplasia vs. atypical complex hyperplasia

8/27(30%)

20/41(49%)

2.465

0.116

Simple hyperplasia vs. endometrioid carcinoma

8/27(30%)

54/103(52%)

4.457

0.035

Simple hyperplasia vs. endometrial serous carcinoma

8/27(30%)

8/21(38%)

0.381

0.537

Simple hyperplasia vs. clear cell carcinoma

8/27(30%)

6/9(67%)

3.50***

0.111**

Atypical complex hyperplasia vs. endometrioid carcinoma

20/41(49%)

54/103(52%)

0.156

0.693

Atypical complex hyperplasia vs. endometrial serous carcinoma

20/41(49%)

8/21(38%)

0.640

0.424

Atypical complex hyperplasia vs. clear cell carcinoma

20/41(49%)

6/9(67%)

4.32***

0.467**

Endometrioid carcinoma vs. endometrial serous carcinoma

54/103(52%)

8/21(38%)

1.433

0.231

Endometrioid carcinoma vs. clear cell carcinoma

54/103(52%)

6/9(67%)

4.18***

0.500**

Endometrial serous carcinoma vs. clear cell carcinoma

8/21(38%)

6/9(67%)

4.20***

0.236

  1. *: We took partitioning Chi-squares when individual comparisons were performed, in order to avoid amplifying the probability to commit type I mistake, p value should be reset as p’ = 1-m√(1-p), “m” represented group numbers. In this case, p’ = 1-5√(1-0.05) = 0.005, so we considered p < 0.005 as statistically significant.
  2. **: When expected cell value was 5 or less, we used Fisher’s exact test.
  3. ***: The expected cell values were 3.50, 4.32, 4.18 and 4.20 for simple hyperplasia vs. clear cell carcinoma, atypical complex hyperplasia vs. clear cell carcinoma, endometrioid carcinoma vs. clear cell carcinoma and endometrial serous carcinoma vs. clear cell carcinoma, respectively.